Insights

Impact Report 2024: Highlights We’re pleased to share our Impact Report 2024 Highlights. Our impact report demonstrates our approach

David joins NorthStar as an Executive Director & Co-Portfolio Manager.

Genex's June quarterly report shows encouraging positive operating cashflow and a strong solar revenue.

UniSuper, the award-winning over $120bn super fund, has appointed NorthStar Impact as a specialist external listed equities manager.

Botanix Pharmaceuticals has announced its BTX 1702 Phase 1b/2 clinical study on papulopustular rosacea has produced clinically meaningful data. 

Volpara Health Technologies (“Volpara”), which provides clinically validated software for the early detection of breast cancer, has been certified

NEXTSTELLIS was approved by the Therapeutic Goods Administration in November 2021.

De.mem treated approximately 550 million litres of water across 15 sites in Australia and Singapore.

We are pleased that Skip Capital and Stonepeak Partners recognise the value in Genex.